ENVISTA: ANNOUNCES ITS AGREEMENT FOR THE SALE OF KAVO TREAMENT UNIT & INSTRUMENT BUSINESS TO PLANMECA (Kind 8-Ok)

ENVISTA ANNOUNCES ITS AGREEMENT TO SELL KAVO TREAMENT UNIT & INSTRUMENT BUSINESS TO PLANMECA

Brea, Calif., September 7, 2021 – Envista Holdings Company (NYSE: NVST) (‘Envista’) right this moment introduced that it has entered right into a binding settlement to promote its KaVo processing unit and devices enterprise to planmeca Verwaltungs GmbH ( ‘Planmeca’) for at $ 455 million, which features a potential top-up fee of as much as $ 30 million. The sale is predicted to shut on the finish of 2021. Income for the enterprise on the market was roughly $ 357 million and $ 317 million in fiscal 2019 and 2020, respectively.

KaVo Therapy Unit & Devices is among the world’s main builders, producers and suppliers of dental remedy items and devices, with a world-renowned model identified for its 100-year historical past of innovation, superior and prime quality manufacturing of dental tools. Based in 1909, KaVo is headquartered in Biberach, Germany, operates in over 60 nations and employs roughly 1,500 individuals.

Envista Holdings Company CEO Amir Aghdaei stated, “Envista is specializing in its strategic priorities to create and optimize a portfolio extra targeted on consumables and workflows. zones. ‘

The enterprise on the market is a part of the Tools and Consumables section of Envista. Envista’s Imaging enterprise, which additionally presently makes use of the KaVo model for sure merchandise, will stay with Envista as a part of the Tools and Consumables section.

It’s anticipated that the KaVo processing unit and instrument enterprise will likely be reported as a discontinued operation as of Envista’s 10-Q submitting within the third quarter of 2021.

The transaction is topic to the satisfaction of sure customary closing situations, together with acquiring relevant regulatory approvals. The transaction will not be topic to financing situations or to a shareholder vote.

JP Morgan Securities LLC acted as monetary advisor and Kirkland & Ellis LLP acted as authorized advisor to Envista in reference to the transaction.

Additional particulars of the transaction will likely be introduced in a present report on Kind 8-Ok which will likely be filed by Envista and out there at www.sec.gov.

ABOUT ENVISTA

Envista is a worldwide household of greater than 30 trusted dental manufacturers, together with KaVo, Kerr, Nobel Biocare and Ormco, united by a typical objective: partnering with professionals to enhance lives. Envista helps its clients present the absolute best affected person care by means of cutting-edge dental consumables, options, applied sciences and providers. Our complete portfolio, comprising dental implants and remedy choices, orthodontics and digital imaging applied sciences, covers roughly 90% of dentists’ medical wants for the prognosis, remedy and prevention of dental situations in addition to the enhancing the aesthetics of the human smile. With a basis made up of the confirmed Envista Enterprise System (EBS) methodology, an skilled administration workforce and a robust tradition based mostly on steady enchancment, dedication to innovation and a deep buyer focus, Envista is nicely outfitted to fulfill end-to-end wants. wants of dental professionals all over the world. Envista is among the world’s largest dental product corporations, with vital market positions in a few of the most tasty segments of the dental product trade. For extra info, please go to www.envistaco.com.

1

FORWARD-LOOKING STATEMENTS

Sure statements contained on this press launch are “forward-looking” statements inside the which means of federal securities legal guidelines. There are a selection of essential elements which might trigger precise outcomes, developments and enterprise choices to vary materially from these steered or indicated by these forward-looking statements, and you shouldn’t place undue reliance on such forward-looking statements. These elements embody, amongst others, the impact of the announcement of the transaction on the Firm’s enterprise relationships, working outcomes, the share worth or the enterprise basically, the prevalence of any occasion or different circumstances which might give rise to the termination of the acquisition contract, the end result of any authorized proceedings which may very well be initiated towards the Firm referring to the transaction, the non-compliance with any of the situations of completion of the transaction, and failure to understand the anticipated advantages ensuing from the transaction, the impression of the COVID-19 pandemic, together with new variants of the virus, the tempo of restoration within the markets during which we function, the situations the US and international financial system, the markets we serve and the monetary markets, the impression of our money owed on our operations and liquidity, developments and uncertainties in commerce insurance policies and rules, commerce contracts tions or progress charges and cyclicality of the markets we serve, fluctuations within the stock of our distributors and clients, the lack of a key distributor, {our relationships} with and the efficiency of our distribution companions, competitors, our capability to efficiently develop and market new services, the potential for inappropriate conduct by our workers, brokers or enterprise companions, our compliance with relevant legal guidelines and rules (together with rules referring to medical units and the healthcare trade, well being), the outcomes of our medical trials and their perceptions, the penalties related to any non-Advertising Authorization of our merchandise, the modifications made to our merchandise which require new authorizations or advertising and marketing authorizations, our potential to successfully handle price reductions and different adjustments within the healthcare trade, our capability ity to establish and efficiently full the suitable strategic acquisitions and investments, our potential to combine the companies we purchase and to attain the anticipated advantages of such acquisitions, situation of the capacities referring to acquisitions, investments and divestitures, vital restrictions and / or potential legal responsibility based mostly on the tax implications of transactions with Danaher, breaches of safety or different disruptions to our pc methods or breaches of knowledge privateness legal guidelines, our potential to adequately defend our mental property, the impression of our enterprise of restructuring on our progress capability, change charge dangers, adjustments in tax legal guidelines relevant to multinational corporations, litigation and different contingent liabilities, together with mental property and environmental, well being and questions of safety, dangers related to pr merchandise, service or software program defects, dangers related to product manufacturing, commodity prices and dietary supplements, our potential to regulate buying and manufacturing capability to mirror market situations, reliance on sources single or restricted provide, the impression of rules on demand for our services, labor points, worldwide financial, political, authorized, compliance and commerce elements, and disruptions associated to struggle, terrorism, widespread protests and civil unrest, pure and man-made disasters, public well being issues and different occasions. Extra info concerning elements that would trigger precise outcomes to vary materially from these forward-looking statements may be present in our filings with the SEC, together with our annual report on Kind 10-Ok for fiscal 2020 and our quarterly studies on type. 10-Q. These forward-looking statements communicate solely as of the date of this press launch and, besides to the extent required by relevant regulation, we assume no obligation to replace or revise any forward-looking statements, whether or not as of the next new info, occasions and developments or different.

CONTACT

Jean Moten

Investor Relations

Envista Holding Firm

200, boul. S. Kraemer, constructing E

Brea, California 92821

Phone: (714) 817-7000

Fax: (714) 817-5450

2

Disclaimer

Envista Holding Firm printed this content material on September 07, 2021 and is solely accountable for the knowledge it comprises. Distributed by Public, unedited and unmodified, on 07 September 2021 13:01:07 UTC.

About Edith J.

Check Also

EnerCom Pre-Revenue Ideas on E&P: Price Inflation in 2022 Shifts from an “If” to a “How A lot” Topic

Oil and fuel 360 By Tim Rezvan-EnerCom, Inc. The third quarter earnings season is about …